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Eﬀects of Hydroxyethyl Starch 130/0.4 on Serum Creatinine
Concentration and Development of Acute Kidney Injury in
Nonazotemic Cats
N.E. Sigrist , N. K€alin, and A. Dreyfus
Background: Hydroxyethyl-starch (HES) solutions might have renal adverse eﬀects in humans and dogs.
Objective: To determine if administration of 6% HES-130/0.4 is associated with an increase in serum creatinine concen-
tration and development of acute kidney injury (AKI) in nonazotemic cats.
Animals: A total of 62 critically ill cats; 26 HES exposed and 36 unexposed.
Methods: Retrospective cohort study (2012–2015). Serum creatinine concentrations were recorded and changes in serum
creatinine concentrations before exposure (baseline) and 2–10 and 11–90 days, respectively, were determined. Development of
AKI was deﬁned as a > 150% increase or >26 lmol/L increase in serum creatinine concentration from baseline. Risk factors,
such as HES administration, cumulative volume of HES (mL/kg) and number of days of HES administration leading to
development of AKI, and change in serum creatinine were analyzed.
Results: Cats in the HES cohort received a mean volume of 98.5  76.2 mL/kg (range, 8–278 mL/kg) HES over a med-
ian of 4 (range, 1–11) days, resulting in a median dose of 20.1 (range, 8–40.5) mL/kg per day. Short-term %change in serum
creatinine concentration (P = 0.40) and development of AKI (P = 0.32) were not signiﬁcantly diﬀerent between cohorts. Mul-
tivariable logistic regression did not identify HES dose in mL/kg (P = 0.33) and number of days of HES application
(P = 0.49) as a risk factor for development of AKI.
Conclusion and Clinical Importance: Hydroxyethyl-starch administration to critically ill nonazotemic cats seems to be safe.
A larger prospective study is required to determine the eﬀect of HES administration at higher dosages and for prolonged
time periods.
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Hydroxyethyl starch (HES) is an artiﬁcial colloidsolution used in both human and veterinary medi-
cine for resuscitation of emergency and critically ill ani-
mals during the past 30 years. Beneﬁcial eﬀects of HES
administration, such as an increase in colloid osmotic
pressure1,2 and blood volume,3,4 are well documented in
dogs. Indications for HES administration in cats are
not well documented. One abstract presented over
10 years ago showed an increase in blood pressure after
HES administration to cats,5 otherwise no clinical stud-
ies evaluating beneﬁts of HES administration in cats
were performed. Nevertheless, HES solutions are widely
used in feline patients for the treatment of hypovolemia,
hypotension, and low colloid osmotic pressure.6–8
Hydroxyethyl-starch administration has been associ-
ated with renal injury in humans.9–13 In veterinary med-
icine, studies investigating potential renal adverse eﬀects
of HES solutions are limited. In dogs, conﬂicting results
were found regarding the incidence of acute kidney
injury (AKI) after HES administration in hospitalized
dogs.14–16 A single study investigated the eﬀect of HES
on renal function in cats and did not identify an
increase in plasma creatinine concentration in cats
exposed to HES-130/0.4.17
The goal of this historical cohort study was to
determine if administration of 6% HES-130/0.4 solutiona
is associated with an increase in serum creatinine
concentration and development of AKI in critically ill,
nonazotemic cats. We distinguished between a short-
term HES eﬀect [increase in serum creatinine concentra-
tion from the last value before exposure (baseline)
to the last recorded value between 2 and 10 days
after exposure] and a long-term eﬀect (increase in
serum creatinine concentration from baseline to the
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last recorded value between 11 and 90 days after
exposure).
Our null hypothesis was that HES exposure did not
eﬀect changes in serum creatinine concentration and
development of AKI in cats being treated with 6%
HES-130/0.4 in an intensive care unit (ICU).
Material and Methods
The computer database of the Vetsuisse Faculty of the Univer-
sity of Zurich was searched for billing of HES and ICU hospital-
ization between January 2012 and December 2015. Cats which
received 6% HES-130/0.4a and had at least 1 serum creatinine
concentration determined before the start of HES administration
as well as at least 48 hours after the start of HES administration,
were eligible to enter the study as exposed cats. Exclusion criteria
consisted of the following: cats with a baseline serum creatinine
concentration above the reference interval (>163 lmol/L;
>1.84 mg/dL), cats which received less than 5 mL/kg HES, admin-
istration of another synthetic colloid besides HES-130/0.4, and
substantial missing data.
All cats, which were hospitalized in the ICU between January
2014 and December 2015, received IV isotonic crystalloid ﬂuids,
and which had at least 2 serum creatinine concentrations measured
>48 hours apart but within 10 days, served as the unexposed
cohort. The same exclusion criteria as above were applied for the
unexposed cats.
Age, sex, breed, and weight were recorded for all cats. The
database and feline records were further evaluated for the cumula-
tive volume (mL) of HES administered and the number of days of
HES administration. Day 0 (baseline) was deﬁned as the ﬁrst day
of HES administration. Total volume of HES per kg body weight
(mL/kg) and corresponding daily dose (mL/kg per day) were cal-
culated for each cat. In addition, the number of crystalloid ﬂuid
days before the ﬁrst serum creatinine concentration measurement,
concurrent blood product administration, diagnosis, duration of
hospital stay, and hospital discharge were extracted.
The diagnosis identiﬁed in the record was further classiﬁed into
one of the 21 groups of the International Statistical Classiﬁcation
of Diseases and Related Health Problems (ICD) System (http://
apps.who.int/classifications/icd10/browse/2016/en). If >1 diagnosis
was present in a cat, the primary presenting problem (the com-
plaint responsible for the cat being in the ICU) was used for the
classiﬁcation. For statistical analysis, the ICD classiﬁcation was
further narrowed into the following groups: abdominal disease
(ICD XI, including parvovirus infection from ICD I and gastroin-
testinal neoplasia from ICD II), urogenital disease (ICD XIV),
trauma (ICD XIX), and other diagnoses (all other ICD classiﬁca-
tions including infectious disease, respiratory, neurologic, and
endocrinologic problems).
Serum creatinine concentrations were extracted from the
hospital database. Some baseline values were measured in the stat
laboratory,b all others in the hospital’s laboratory,c with both
machines having comparable upper reference intervals (160 and
163 lmol/L, respectively). The baseline serum creatinine concen-
tration of the exposed group was deﬁned as the last concentration
available before HES administration. In the unexposed cohort, the
ﬁrst available serum creatinine concentration measured after
admission to the ICU was used as baseline serum creatinine con-
centration. Serum creatinine concentrations were then recorded
each available day until day 90. During the time period of days 2–
10, the highest and the last serum creatinine concentration was
determined and used for statistical analysis of the short-term
eﬀect. Additionally, the last serum creatinine concentration
between days 11 and 90 was determined for analysis of the long-
term inﬂuence. Serum creatinine changes were calculated as
absolute change in serum creatinine concentration (delta crea-
tinine) from baseline to the last and highest concentration within
2–10 days. Additionally, the change in percent (%change) from
baseline to the last and highest serum creatinine concentration
within 2–10 days and from baseline to the last serum creatinine
concentration within 11–90 days was calculated. Based on the vet-
erinary acute kidney injury (VAKI) scoring system,18 development
of AKI was deﬁned as an absolute increase in serum creatinine
concentration >26 lmol/L (0.3 mg/dL) or increase of >150% in
serum creatinine concentration from baseline.
Data Analysis
The data were entered into a spreadsheet and were double-
checked by 2 of the authors. Statistical analyses were performed
by SPSSd and Stata 10.e Normality was tested for continuous data
with Shapiro-Wilk. Fisher’s exact test or Chi-square test was used
for determination of an association between categorical variables,
whereas a Mann–Whitney or independent t-test was used for con-
tinuous data.
The primary outcomes were %change in serum creatinine con-
centration (%change) and development of AKI (as deﬁned above)
from baseline to the last serum creatinine concentration within 2–
10 days of HES administration (short-term eﬀect). The secondary
outcome was %change in serum creatinine concentration from
baseline to the last serum creatinine concentration within 11–
21 days of HES administration (long-term eﬀect).
Potential risk factors including the following main exposure
variables (a) HES administration (yes/no), (b) cumulative volume
of HES per kg body weight (mL/kg), (c) mL/kg per day, or
(d) number of days HES was administered, and age, sex, ICD
score, duration of hospital stay, red blood cell, and plasma trans-
fusion are listed in Table 1. The association between the outcomes
“%changelast” (%change in serum creatinine concentration from
baseline to the last recorded concentration within 2–10 days) and
“AKI” (development of AKI) with exposure variables listed in
Table 1 was analyzed in two steps. First, bivariably by univariable
linear regression analysis and secondly, by multivariable linear
regression (mlrm) and logistic regression (lrm) modeling. We built
four mlrm and lrm, assessing the association between the outcome
“%changelast” and “AKI”, respectively, and the following main
exposure variables (a) HES administration (yes/no), (b) cumulative
volume of HES per kg body weight (mL/kg), (c) mL/kg per day,
or (d) number of days HES (Table 1), by a manual stepwise for-
wards and backwards procedure. Other exposure variables and
potential confounders listed in Table 1 were included in the model
if they improved the model ﬁt assessed by adjusted r-squared (mlrm)
and likelihood ratio test (lrm). To identify observations with
potential inﬂuence on regression coeﬃcient estimates, we per-
formed linear regression diagnostics, assessing studentized residuals
and leverage, and for overall measures of inﬂuence, we assessed
Cook’s D. We tested for a normal distribution and homoscedastic-
ity of residuals and whether there was a linear relationship
between the outcome and exposure variables. The tested null
hypotheses were that HES administration in cats was not associ-
ated with the %change in serum creatinine concentration and with
development of AKI, when adjusting for potential confounding
factors.
Statistical signiﬁcance was set at P < 0.05 for all analyses.
Results
A total of 62 cats met the inclusion criteria. The
exposed cohort (HES-exposed cohort) included 26
(42%) cats with a median age of 38 months (range,
3–217 months) and a median weight of 3.9 kg (range,
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2–7 kg). Twelve (46%) cats were female and 14 cats
(54%) were male. The European Shorthair cat was most
prevalent (65%), followed by Main Coon, Persian, and
Norwegian forest cat (8%, each). The HES cohort
received a mean total cumulative volume of
98.5  76.2 mL/kg (range, 8–278 mL/kg) HES-130/0.4
over a median of 4 days (range, 1–11 days). This
resulted in a mean dose of 20.1  8.2 mL/kg per day
(range, 8–40.5 mL/kg per day).
The unexposed cohort included 36 (58%) cats with a
median age of 108 months (range, 11–218 months) and
a median weight of 4.3 kg (range, 3–10 kg). Sixteen
(44%) cats were female and 20 cats (56%) were male.
Several breeds were identiﬁed including 81% European
Shorthair cats and 6% Birman being the most common.
The 2 cohorts were similar in terms of sex, breed,
weight, days of ﬂuid treatment before the ﬁrst serum
creatinine measurement, number of hospital days, and
day of last serum creatinine concentration measure-
ment, but diﬀered signiﬁcantly in age (P = 0.030) and
diagnosis (P = 0.015) (Table 1). The HES cohort
received signiﬁcantly more red blood cell transfusions
(P = 0.027), plasma transfusions (P = 0.004) and pre-
sented with a signiﬁcantly lower serum albumin
(20.4  6 g/L versus 27.7  6 g/L; P < 0.001). Hospital
discharge was not signiﬁcantly diﬀerent between cohorts
(33/36 in the HES unexposed; 19/26 in the exposed
cohort; P = 0.054).
Serum creatinine concentrations at the evaluated time
points are summarized in Table 2. The unexposed
cohort showed signiﬁcantly higher mean serum crea-
tinine concentrations at baseline and last measurement
within 2–10 days. The change in serum creatinine
concentration (%changelast) from baseline to last serum
creatinine concentration within 2–10 days as well as
from baseline to last serum creatinine measurement
within 11–90 days was not signiﬁcantly diﬀerent
between the two cohorts (Table 2).
Based on the above AKI deﬁnition (increase in serum
creatinine concentration >26 lmol/L (0.3 mg/dL) or
increase from baseline >150%), 11/36 unexposed cats
(31%) and 5/26 (19%) HES-exposed cats developed
AKI within 2–10 days (P = 0.24). There was no diﬀer-
ence in AKI development using highest versus last
serum creatinine concentration within 2–10 days (data
not shown).
The univariable analysis did not identify a signiﬁcant
association between HES administration and short-term
%change in serum creatinine concentration (P = 0.395)
and development of AKI (P = 0.32) (Tables 2 and 4).
The long-term change in serum creatinine concentra-
tion (baseline to last value within 11–90 days) did not
diﬀer statistically between HES exposed and unexposed
cats (P = 0.57) (Table 2). Four of 17 (24%) unexposed
and 1/9 (11%) HES-exposed cats showed an increase
>150% from baseline to the last serum creatinine con-
centration within 11–90 days (P = 0.42).
Multivariable Analysis
Multivariable analysis was performed for the out-
comes % increase in serum creatinine concentration
from baseline to the last measurement within 2–10 days
(%changelast) and development of AKI. None of the
four multivariable linear regression models revealed a
statistically signiﬁcant association between the outcome
Table 1. Frequencies of predictor variables in cats exposed and unexposed to 6% HES-130/0.4.
Parameter (Exposure/Risk Factor) Categories
Unexposed (n = 36) HES Exposed (n = 26)
P-Valuen Median (Min–Max) Mean  SD n Median (Min–Max) Mean  SD
Age (month) Continuous 36 108 (11–218) 25 38 (3–217) 0.030
Weight (kg) Continuous 36 4.3 (3–10) 26 3.9 (2–7) 0.15
HES cumulative dose (mL/kg) Continuous 0 0 26 98.5  76.2
HES number of days (d) Continuous 0 0 26 4 (1–11)
HES dose per day
(mL/kg per day)
Continuous 0 0 26 20.1  8.2
Hospital stay (days) Continuous 36 9 (3–37) 26 8.5 (1–45) 0.89
Crystalloid ﬂuid days before
HES start/ﬁrst crea in ICU
Continuous 36 1 (0–5) 26 1 (0–2) 0.19
Parameter (Exposure/Risk Factor) Categories n/N % n/N % P-Value
Sex Male 20/36 56 14/26 54 0.55
Female 16/36 44 12/26 46
Diagnosis ICD 19 (Trauma) 15/36 42 12/26 46.2 0.015
ICD 11 (abdominal) 4/36 11 10/26 38.5
ICD 14 (urogenital) 1/36 3 1/26 3.8
ICD (others) 16/36 44 3/26 11.5
Red blood cell transfusion Yes/no 4/36 11 9/26 34.6 0.027
Plasma transfusion Yes/no 2/36 6 9/26 34.6 0.004
HES application Yes/no 0/36 0 26/26 100
Crea, serum creatinine concentration; ICD, International Statistical Classiﬁcation of Diseases and Related Health Problems; ICU,
intensive care unit.
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“%changelast” and one of the four main exposure vari-
ables (a) HES administration yes/no (P = 0.38), (b)
total HES volume in mL/kg (P = 0.24), (c) HES days
(P = 0.13), and (d) HES mL/kg per day (P = 0.51),
once adjusted for potential confounding variables. We
adjusted for the following exposure variables (potential
confounders): red blood cell transfusion, plasma trans-
fusion, age, sex, duration of hospital stay, and ICD
score. However, only the duration of hospital stay
improved the model ﬁt and remained in the ﬁnal model
(Table 3). All 4 tested HES exposure variables revealed
a negative coeﬃcient, meaning that HES administration
was associated with a reduction in serum creatinine
concentration. However, this association was not statis-
tically signiﬁcant (Table 3).
In the multivariable logistic regression model, the
simple model had the best ﬁt and did not identify HES
administration, cumulative HES dose in mL/kg and
mL/kg per day and number of days of HES application
as a risk factor for development of AKI (P = 0.32,
P = 0.33, P = 0.19 and P = 0.49, respectively) (Table 4).
Multivariable analysis revealed that the administration
of HES did not show a statistically signiﬁcant eﬀect on
the change of serum creatinine concentration and AKI.
Linear and logistic regression diagnostics revealed a
few outliers and residuals. Their removal did not have
an eﬀect on the coeﬃcients of the regression models
and was therefore kept in the models.
Discussion
Our study investigating the eﬀect of HES 130/0.4
administered to nonazotemic cats did not identify an
increase in serum creatinine concentration both within
10 (short-term) and within 90 days (long-term) when
compared to unexposed cats. Development of AKI was
further not statistically signiﬁcantly diﬀerent between
HES exposed and unexposed cats.
Table 2. Serum creatinine concentrations (crea) in cats exposed and unexposed to 6% HES-130/0.4.
Variable
Unexposed (n = 36) HES Exposed (n = 26)
P-Valuen
Mean  SD
or Median Min Max n
Mean  SD
or Median Min Max
Crea day 0 (lmol/L)
(mg/dL)
36 113.5  36
1.28  0.4
39
0.44
163
1.84
26 84.3  35
0.95  0.4
21
0.24
143
1.62
0.001
Last crea within days 2–10 (lmol/L)
(mg/dL)
36 111.9  53
1.27  0.6
25
0.28
246
2.78
26 73.8  32
0.84  0.4
18
0.2
140
1.58
0.001
% change between day 0 and last
Crea day within days 2–10 (%)
36 103.8  45 17 194 26 94.5  38 40 167 0.40
Day last crea for long-term
evaluation (day)
17 13.0 11 62 9 17.5 11 76 0.19
Last crea within days 11–90 (lmol/L)
(mg/dL)
17 123.7  45
1.4  0.5
42
0.48
229
2.59
9 100.8  21
1.14  0.2
58
0.66
133
1.50
0.16
% change between day 0 and last
Crea within days 11–90 (%)
17 115.3  48 35 209 9 104.4  40 41 182 0.57
Crea, serum creatinine concentration.
Table 3. Multivariable linear regression analysis on the eﬀect of exposure variables on change of serum creatinine
concentrations in cats (n = 62) exposed and unexposed to 6% HES-130/0.4.
Model Eﬀect on Change of Creatinine (% changelast) Coeﬃcient P-Value 95% CI Adjusted r2
1 HES yes/no 9.55a 0.38 31.0–11.87 0.032
Number of hospital days 1.21 0.076 2.56–0.13
Intercept 117.44 0 97.0–138.0
2 HES mL/kg 0.09 0.24 0.25–0.06 0.042
Number of hospital days 1.05 0.13 2.41–0.32
Intercept 115.38 0 97.0–134.0
3 Number of days of HES administration 3.05 0.13 7.02–0.93 0.057
Number of hospital days 0.99 0.15 2.35–0.36
Intercept 116.56 0 98.0–135.15
4 HES mL/kg per day 0.31 0.51 1.26–0.63 0.054
Number of hospital days 1.20 0.079 2.55–0.14
Intercept 115.94 0 95.95–135.94
aMeaning: The change in serum creatinine concentration was reduced by 9.55 units with the administration of HES, assuming all other
variables were held constant. In simple words: HES administration is associated with a reduction in serum creatinine concentration.
However, this association is not statistically signiﬁcant, as P-value is >0.05.
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Our ﬁndings are in accordance with the canine
studies and the single feline study that have investigated
the eﬀect of the same tetrastarch (6% HES-130/0.4)
solution.15–17 The feline study evaluated the increase in
plasma creatinine concentration between admission and
highest creatinine concentration during hospitaliza-
tion.17 Our study protocol was slightly diﬀerent, as we
chose the last serum creatinine concentration before
HES administration as the baseline serum creatinine
concentration and follow-up serum creatinine concen-
trations had to be measured at least 48 hours after
baseline measurement. With this approach, we
decreased the possibility of falsely higher admission
serum creatinine concentrations due to hemoconcentra-
tion, which can hide an increase in serum creatinine
concentration after HES exposure in combination with
volume expansion. We further decided to analyze the
association between HES administration and the last
rather than the highest serum creatinine concentration
within 2–10 days. While the increase from baseline to
the highest serum creatinine concentration can better
reﬂect a potential adverse eﬀect of HES administration,
we believe the last serum creatinine concentration to be
more relevant for the cat’s clinical condition. However,
the last serum creatinine concentration was very similar
to the highest and did not change the study results
when used as the outcome (data not shown).
Our study is the ﬁrst investigating the relationship of
dose and time of HES administration on changes in
serum creatinine concentrations in cats. In contrast to a
recent canine study evaluating the same HES solution,16
we did not identify the number of days of HES adminis-
tration as a risk factor of AKI development within
10 days of HES exposure.
In human studies and in 1 canine study, a dose-
response relationship of HES administration has been
proposed.14,19 The Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicine Agency
therefore recommends using HES solutions at the low-
est eﬀective dose, generally for a maximum of 24 hours
and avoiding administration as a constant rate infusion
(CRI)20. In our study, the volume of HES administra-
tion was kept wide on purpose, as HES volume per kg
body weight was analyzed as possible risk factor for an
increase in serum creatinine concentration. A higher
HES dose per kg body weight and per kg body weight
per day was not associated with an increase in serum
creatinine concentration. This is in accordance with our
study in dogs15 and the last Cochrane review21 that did
not ﬁnd an association between the HES dose and
development of AKI or need for renal replacement ther-
apy. In humans, cumulative HES dosages as low as
39 mL/kg have been shown to induce AKI.22 In con-
trast, dosages of up to 86 and 94 mL/kg HES-130/0.4
did not induce AKI in dogs and cats, respectively.15–17
The cats in our study received a median cumulative
HES dose of 99 mL/kg, resulting in a median daily dose
of 20 mL/kg per day. While the total cumulative HES
dose is comparable or even higher to other studies, the
daily dose administered was below the maximal dose
recommended by the manufacturera (30 mL/kg per
day). The given sample size of 62 cats was suﬃcient for
the detection of a signiﬁcant diﬀerence between the 2
cohorts if the incidence in the unexposed cohort was
0.3, assuming a relative risk of 2.2, with the desired
conﬁdence level of 0.95 and a power of 0.85. However,
to detect a signiﬁcant diﬀerence between the two
cohorts for a smaller relative risk as in this study, the
sample size would have had to be larger. For example, to
detect a relative risk of 1.1, the sample size would have
had to be 8602 cats (4301 in each cohort; http://epitools.
ausvet.com.au/content.php?page=cohortSS). Therefore,
we conclude that a daily dose of 20 mL/kg per day in
nonazotemic cats seems to be safe; however, a larger
sample size is needed to conﬁrm our results.
As serum creatinine lags behind renal injury23, we
only included cats with follow-up serum creatinine con-
centrations >48 hours after exposure. Serum creatinine
concentration could also be an insuﬃcient marker of
renal function.23 However, histologic changes have
been described in the kidneys within 24 hour of HES
administration24 and an increase in serum creatinine
concentration after a decrease in glomerular ﬁltration
rate is expected after 24–48 hours.10,25 The mechanism
of action of renal impairment with HES administration
in humans is not fully understood. High concentrations
of HES molecules have been identiﬁed in the proximal
renal tubular cells of various species.26 Cellular uptake
of HES leads to osmotic nephrosis, characterized by
accumulation of intracellular water, cytoplasmic swel-
ling, and cellular disruption.27,28 No histopathologic
studies showing HES accumulation in feline renal tubu-
lar cells could be identiﬁed; however, there is no reason
to believe that HES does not accumulate in feline
renal tubular cells as it accumulates in many other
species.26,28
Several studies indicated an increased risk of renal
injury in human patients exposed to HES.9–13 An
increase in the need for renal replacement therapy
(RRT) and development of AKI is predominantly docu-
mented in humans with sepsis that was exposed to HES
solutions.9–11 We did not analyze the eﬀect of HES in
subgroups of cats with sepsis. Several studies in trauma
and surgical patients do not support the increased need
for RRT as seen in septic patients13,29–31 implying either
variable eﬀects of HES or diﬀerent predispositions in
diﬀerent patient populations.15,16,19,32 Given the most
Table 4. Multivariable logistic regression analysis on
the eﬀect of exposure variables on development of AKI
within 2–10 days after exposure in cats (n = 62)
exposed and unexposed to 6% HES-130/0.4.
Eﬀect on Development of AKIa
Odds
Ratio P-Value 95% CI
HES administration yes/no 0.54 0.32 0.16–1.81
Total HES dose (mL/kg) 0.99 0.33 0.98–1.01
Number of days of HES
administration
0.84 0.19 0.64–1.09
HES mL/kg per day 0.98 0.49 0.93–1.04
aThe simple model had the best ﬁt.
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common ICD classiﬁcations of our study population,
our ﬁndings are better compared to studies focusing on
trauma and surgical human patients. Regarding the dif-
ference between septicemic patients and other popula-
tions, the renal impairment seems to occur independent
of inﬂammation even though changes are pronounced
with concurrent sepsis in a rat model of septic AKI.24
Renal injury induced by HES treatment therefore might
be more severe and clinically important in septic
patients, requiring further studies in both septicemic
dogs and cats.
The diﬀerent ﬁndings in our study compared to the
human studies might also be caused by diﬀerent HES
solutions investigated. In a porcine renal perfusion
model, HES administration leads to impairment of
renal function and induction of interstitial proliferation
and macrophage inﬁltration within 6 hours. The eﬀect
was signiﬁcantly more pronounced with HES 200/0.5
compared to the tetrastarch HES 130/0.42.33 On the
other hand, in an in vitro model of human proximal
tubular cells, it was concluded that not the type or size
of the HES molecule but rather the number of mole-
cules or cumulative dose was responsible for proximal
tubular cell harm.34 In dogs, the type of HES might
inﬂuence renal injury, as administration of 10% HES
250/0.5 leads to an increase in AKI14 while 6% HES
130/0.4 did not.15,16 The 2 available studies in cats
examined the same tetrastarch; therefore, conclusions
regarding the type (pentastarch versus tetrastarch) or
concentration (10% versus 6%) remain unanswered.
The available data in cats treated with 6% HES 130/0.4
imply that this tetrastarch is safe when administered to
nonazotemic cats.
Long-term eﬀects on survival caused by tissue accu-
mulation of HES are expected 20 days after initial
exposure in humans.11 The PRAC recommends moni-
toring of serum creatinine concentrations for 90 days
after exposured. Therefore, long-term monitoring of
renal function in cats is as important as short-term eval-
uation. As discussed above, increases in serum creatinine
concentrations are expected within 2–4 days after renal
injury and renal injury by HES has been identiﬁed histo-
logically after 24 hours of HES administration.10,23–25
We therefore deﬁned short-term evaluation as changes
between baseline and 2–10 days and long-term evalua-
tion as changes between baseline and 11–90 days.
The low number of animals available for long-term anal-
ysis and median days of last creatinine determination
being <20 days limits our ﬁndings regarding long-term
evaluation and linear regression analysis investigating
potential risk factors for a long-term eﬀect of HES
therefore was not performed. Further prospective studies
investigating long-term eﬀects of HES administration
are needed.
As does any retrospective study, our study has several
limitations. First, the exposed and unexposed cohorts dif-
fered at baseline in terms of age, baseline serum albumin,
and transfusion requirements. As these factors also are
indications for HES administration being required, it
would be diﬃcult to ﬁnd a matching control group.
Transfusion requirements and age were not signiﬁcant
risk factors in the linear regression models and did not
improve model ﬁt. Therefore, we assume that our study
results were not strongly biased by these diﬀerences
between the exposed and unexposed cohorts. Second, the
diagnosis in cats in the two cohorts was diﬀerent, with
more cats in the HES group presenting with an abdomi-
nal problem and fewer cats presenting with endocrino-
logic problems and heart disease. This could account for
the signiﬁcantly lower baseline and follow-up serum crea-
tinine concentration in the HES cohort. Again, diagnosis
was not a signiﬁcant risk factor in the linear regression
models and did not improve model ﬁt. Illness severity
scores were not performed due to incomplete data and
reasons for HES administration, such as hypotension
and hypoalbuminemia, are part of the illness severity
score parameters and eventually lead to diﬀerent scores
between HES exposed and unexposed cats as seen in pre-
vious studies.14,17 Therefore, we do not believe that
description of illness severity scores are beneﬁcial in
describing the patient population. Third, the volume of
crystalloid ﬂuid administration before determination of
baseline serum creatinine concentration might have an
eﬀect on changes in serum creatinine concentration. We
did not determine the cumulative dose of crystalloids
before or after exposure. However, the number of days
of crystalloid ﬂuid treatment before exposure was not
statistically diﬀerent between exposed and unexposed
cats, and therefore, we believe that cats received compa-
rable volumes of crystalloid ﬂuids before the ﬁrst serum
creatinine measurement and hydration status therefore
can be assumed to be comparable. After inclusion, cats
in both cohorts received at least maintenance crystalloid
requirements independently of HES administration.
Fourth, data were collected retrospectively and serum
creatinine concentrations were not available at multiple,
predeﬁned time points. Some cats had serum creatinine
concentrations measured several times, while in others,
only a single postexposure value was available. However,
all other available studies investigating HES administra-
tion in veterinary patients also did not serially measure
serum creatinine concentrations; therefore, our results
are comparable to those results.14–17 Further prospective
studies with a higher number of cats, speciﬁcally septic
cats, and investigating the eﬀect of higher and longer
HES administration on serial serum creatinine concen-
trations or renal histopathology results are required to
investigate the safety of HES administration in cats.
In conclusion, 6% HES-130/0.4 administration to
critically ill nonazotemic cats was not associated with
an increase in serum creatinine concentration both
short- and long-term or development of AKI within
10 days. We conclude that 6% HES-130/0.4 administra-
tion in moderate dosages seems to be safe in nona-
zotemic cats.
Footnotes
a Voluven (HES 130/0.4) 6% solution, http://compendium.ch/
mpro/mnr/15871/html/de Accessed November 22, 2016.
6 Sigrist et al
b Fujiﬁlm Dri-Chem 3500i; Polymed Medical Center, R€umlang,
Switzerland.
c Cobas Integra 800, Roche Diagnostics, Rotkreuz, Switzerland.
d IBM SPSS v.21 for Mac OS X; IBM Corporation, New York,
NY.
e StataCorp, Data Analysis and Statistical Software, College
Station, TX, FDA inlet: http://www.fda.gov/downloads/. . ./
UCM083138.pdf.
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